A New Hope in the Fight Against Antimicrobial Resistance with Artificial Intelligence
Minh-Hoang Tran,Ngoc Quy Nguyen,Hong Tham Pham
DOI: https://doi.org/10.2147/IDR.S362356
2022-05-27
Infection and Drug Resistance
Abstract:Minh-Hoang Tran, 1 Ngoc Quy Nguyen, 2 Hong Tham Pham 1, 3 1 Department of Pharmacy, Nhan Dan Gia Dinh Hospital, Ho Chi Minh City, Vietnam; 2 Institute of Environmental Technology and Sustainable Development, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam; 3 Department of Pharmacy, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam Correspondence: Hong Tham Pham, Department of Pharmacy, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam, Tel +84 919 559 085, Email Recent years have witnessed the rise of artificial intelligence (AI) in antimicrobial resistance (AMR) management, implying a positive signal in the fight against antibiotic-resistant microbes. The impact of AI starts with data collection and preparation for deploying AI-driven systems, which can lay the foundation for some effective infection control strategies. Primary applications of AI include identifying potential antimicrobial molecules, rapidly testing antimicrobial susceptibility, and optimizing antibiotic combinations. Aside from their outstanding effectiveness, these applications also express high potential in narrowing the burden gap of AMR among different settings around the world. Despite these benefits, the interpretability of AI-based systems or models remains vague. Attempts to address this issue had led to two novel explanation techniques, but none have shown enough robustness or comprehensiveness to be widely applied in AI and AMR control. A multidisciplinary collaboration between the medical field and advanced technology is therefore needed to partially manage this situation and improve the AI systems' performance and their effectiveness against drug-resistant pathogens, in addition to multiple equity actions for mitigating the failure risks of AI due to a global-scale equity gap. Keywords: antibiotic, antimicrobial resistance, infection, artificial intelligence In recent years, following the development of technology, artificial intelligence (AI) has shown remarkable effectiveness in controlling antimicrobial resistance (AMR), 1 one of the top ten global public health threats that humans have to face in this century. 2 This implies a positive signal in our fight against drug-resistant bacteria, right amid this global crisis. Although the research and deployment of AI-based applications might require modern technology, the resultant products, algorithms, or procedures are more accessible to the end-users, even in poor quality healthcare settings, thanks to AI's automation and efficiency, therefore, confirming its influence and equity role in AMR control. First, the role of AI starts with one of its unique features: data. Clinical data, aside from being a critical element in AI, 3 can also give us a good track of the situation inside a healthcare setting, especially about the epidemiology and characteristics of the pathogens. Coincidently, and luckily, before deploying any AI-driven systems, the data collection process itself has set the foundation for other fields and disciplines in health sciences by providing a large amount of information and insights, which could promote other potential infection control strategies. One of the most prominent secondary applications of AI-deploying data is to support antimicrobial stewardship program (AMS), an approach to optimize antibiotic use, improve patient outcomes, and mitigate AMR, healthcare-associated infections, and healthcare costs. 4 Healthcare and microbial data can be applied in many different ways to maximize the effects of AMS, specifically in countries that lack access to effective antimicrobial treatments. With a vast amount of daily healthcare data, not only can we efficiently deploy AI-based systems but also AMS to more comprehensive and more profound extents, which could possibly predict the epidemiology of nosocomial pathogens. This would allow us to prevent many multidrug-resistant bacterial infections, lowering antibiotic use and eventually limiting the prevalence and spread of AMR. 5 Second—and probably one of AI's most well-known applications—AI-based systems can assist critically in selecting and identifying molecular structures, proving their important role in drug discovery and, in this case, antibiotic discovery. In recent decades, private sectors have shown fewer preferences in developing new antibiotics due to the lack of economic incentives, 6 making the threat of antimicrobial resistance more intimidating in the upcoming years. With assistance from AI models, scientists can now shorten this process with an increasing accuracy rate of lead compound identification at a much lower screening cost. Initially, Stokes et al had discovered halicin, a broad-spectrum antibacterial molecule that is highly effective agai -Abstract Truncated-
pharmacology & pharmacy,infectious diseases